The Role of Peptides in Managing peptides for type 2 diabetes: be...

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

In adults with type 2 diabetes inadequately controlled on GLP-1 receptor agonists, emerging peptide therapies such as glucagon receptor antagonists and dual/triple receptor agonists offer additional mechanisms to improve glycemic control by reducing hepatic glucose production and enhancing insulin secretion. Amylin analogs and other novel peptides serve as adjuncts targeting postprandial glucose and insulin resistance, but patient selection, gradual dose titration, and monitoring of efficacy and side effects remain essential.

Peptides for type 2 diabetes: beyond GLP-1

In adults with type 2 diabetes, GLP-1 receptor agonists typically lower HbA1c by 1.0-1.5% over 24 weeks, but around 20-30% of patients fail to achieve optimal glycemic control with GLP-1 alone. While GLP-1 analogs like liraglutide at 1.8mg daily remain mainstays, emerging peptide therapies target complementary pathways—offering renewed hope for those refractory to conventional treatments.

Why look beyond GLP-1?

GLP-1 receptor agonists stimulate insulin release, suppress glucagon, slow gastric emptying, and promote satiety. Despite these multiple mechanisms, they don't address other key factors in type 2 diabetes: insulin resistance and pancreatic beta-cell dysfunction. For many patients, especially those with long-standing disease or significant insulin resistance, GLP-1-based therapy provides incomplete improvement.

Moreover, gastrointestinal side effects—nausea or vomiting—limit tolerability at higher doses for some. That's where peptides targeting alternate pathways come into play.

Glucagon receptor antagonists vs GLP-1 agonists

Glucagon drives hepatic glucose production, which worsens hyperglycemia. Blocking glucagon receptors can reduce fasting glucose independently of insulin secretion.

• Example: The peptide glucagon receptor antagonist des-his1-[Glu9] glucagon amide reduces fasting blood glucose by ~20 mg/dL after 4 weeks of daily dosing at 250 mcg subcutaneously, based on early-phase trials.
• When compared to GLP-1 agonists, glucagon antagonists directly target hepatic glucose output rather than enhancing insulin secretion.
• This makes them particularly valuable in patients with advanced beta-cell dysfunction where insulin secretagogues fail.

Dual or triple receptor agonists

Compounds combining GLP-1 activity with other receptor targets have attracted attention. Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces greater HbA1c reductions (up to 2.4% at 15mg weekly doses) and weight loss than GLP-1 monoagonists in the SURPASS trials (Frías et al., 2021).

What about non-incretin peptides? Dual or tri-agonists including glucagon receptor activity can simultaneously enhance insulin secretion, suppress glucagon, slow gastric emptying, and increase energy expenditure through increased lipolysis.

For example, some glucagon-GLP-1 co-agonists deliver weight loss benefits exceeding liraglutide 3.0mg daily, coupled with meaningful glucose control improvements. However, the increased risk of nausea and potential cardiac effects requires cautious titration over several weeks, starting at doses like 5 mcg daily and titrating up to 25 mcg weekly, depending on the compound.

Amylin analogs: a complementary peptide

Amylin is co-secreted with insulin by beta-cells and slows gastric emptying, suppresses postprandial glucagon, and promotes satiety. Pramlintide, a synthetic amylin analog, dosed at 60 mcg subcutaneously before meals, reduces postprandial glucose spikes by up to 30% and modestly lowers HbA1c (0.3-0.5%) when added to existing regimens.

Amylin analogs serve as adjuncts rather than replacements, especially useful in patients with significant postprandial hyperglycemia despite basal insulin. Unlike GLP-1, amylin acts primarily on the central nervous system to regulate appetite and gastric emptying, providing a different but complementary mechanism.

Other promising peptides

• Neuropeptide Y antagonists: May improve insulin sensitivity by modulating hypothalamic appetite circuits, though clinical data remain preliminary.
• Bariatric surgery mimetic peptides: Such as fibroblast growth factor 19 (FGF19) analogs, manipulate bile acid metabolism influencing glucose homeostasis.
• Zenpepins: Novel insulinotropic peptides under preclinical evaluation that stimulate beta-cell proliferation and reduce apoptosis.

While these are experimental, they highlight the expanding peptide landscape targeting diverse pathophysiologic mechanisms in type 2 diabetes.

Comparing peptides for type 2 diabetes: efficacy and limitations

• GLP-1 agonists: Strong insulinotropic effect, weight loss, moderate GI side effects, HbA1c drop ~1.0-1.5%.
• Glucagon antagonists: Reduce hepatic glucose output, adjunct for insulin-resistant or beta-cell failure diabetics, limited long-term safety data.
• Dual/triple agonists: Potentially superior efficacy (HbA1c >2%), enhanced weight loss, but side effects and cost can limit use.
• Amylin analogs: Improve postprandial control, adjunctive therapy, often used with insulin, modest HbA1c effect.

Choosing a peptide or combination depends on clinical phenotype — for example, patients with obesity and insulin resistance may benefit more from dual GLP-1/GIP agonists, while those with significant fasting hyperglycemia and beta-cell loss may find glucagon antagonists helpful.

Clinical implications and monitoring

In clinical practice, routine metrics remain key:

• Monitor HbA1c every 3 months to assess efficacy.
• Track body weight and BMI for metabolic effects.
• Watch renal and hepatic labs, especially with novel peptides, since long-term safety profiles are emerging.
• Patient education about side effects—especially GI symptoms—with gradual dose titration improves adherence.

Actionable clinical takeaway

For type 2 diabetes patients inadequately controlled on metformin and GLP-1 agonists (e.g., HbA1c >8.0% after 6 months on liraglutide 1.8mg daily), consider introducing a glucagon receptor antagonist peptide at 250mcg subcutaneously once daily in a monitored 8-week trial. Track fasting plasma glucose and insulin resistance parameters (HOMA-IR), aiming for at least a 15% reduction. Adjust concomitant medications responsibly and evaluate side effects. This approach targets hepatic glucose overproduction, complementing incretin therapy and broadening glycemic control strategies beyond GLP-1 alone.